What EFFIK does

EFFIK is a French pharmaceutical laboratory founded in 1992 and headquartered in Meudon, operating as the wholly-owned French subsidiary of the Italian ITALFARMACO group (acquired in 2015). The company employs 110+ collaborators and specializes primarily in women's health, with a diversified portfolio spanning prescription medications (contraceptives, menopause therapies, anti-infectives, anti-nausea treatments for pregnancy), CE-marked Class IIa medical devices (vaginal gels, muco-adhesive ovules, connected pelvic floor electrostimulators), dietary supplements (the NATALBEN preconception/pregnancy/postpartum range using Quatrefolic 5-MTHF), and cosmetics. Since 2016 EFFIK has expanded beyond its women's health core into neurology via TEGLUTIK (riluzole) for ALS, and in 2023 established a dedicated rare diseases team focused on Duchenne Myopathy. The company's technology base includes proprietary pharmaceutical formulations (e.g., Quatrefolic 5-MTHF, fenticonazole-based antifungals), Class IIa medical devices with novel mechanism architectures (Geliofil Protect, Polybactum), and a connected electrostimulation device (GynEffik Connect) controlled via a smartphone application. EFFIK operates a B2B go-to-market model distributing exclusively through French pharmaceutical wholesale distributors (grossistes répartiteurs), hospital/healthcare establishments (établissements de santé), and pharmacies (pharmacies d'officine), supported by a field sales force of certified medical representatives (Délégués médicaux) and an integrated call center for order support and medical information. Revenue is generated through one-time sales of prescription drugs, medical devices, and dietary supplements at prices determined by the French pharmaceutical distribution system, with no public pricing disclosed. Customer segments span the full women's health lifecycle (contraception, fertility, pregnancy, postpartum, menopause, intimate comfort), healthcare professionals (gynecologists, midwives, GPs, pharmacists), institutional buyers (hospitals, wholesalers), and — more recently — neurology and rare disease patient populations.

Name

EFFIK

Legal name

EFFIK SA

Website

https://effik.fr

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

11–50 employees

Short description

EFFIK is a French pharmaceutical laboratory founded in 1992 and owned by ITALFARMACO, specializing in women's health (contraception, fertility, pregnancy, menopause, intimate comfort) with recent expansion into neurology and rare diseases, distributing its prescription medications, medical devices, and dietary supplements through French pharmacies, hospitals, and wholesalers.

Ownership category

akta.pro rank

Headquarters

HQ city

Meudon

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Marketing or Sales, Technology or R&D, Operations

Revenue model

1. Prescription Pharmaceuticals: EFFIK develops and distributes prescription medicines including hormonal contraceptives (TRIAFEMI, CARLIN, DESOBEL, DROSPIBEL, FÉMI), menopause treatments (ESTIMA, BLISSEL), anti-infectives (LOMEXIN, TERLOMEXIN, BEAGYNE), neurological treatments (TEGLUTIK/Riluzole for ALS), and nausea treatments (CARIBAN). Revenue is generated through wholesale and pharmacy distribution.
2. Medical Devices: Class IIa medical devices including vaginal gels (Geliofil Protect), intimate comfort products (AINARA), pelvic floor electrostimulators (GYNEFFIK 2.0, Gyneffik Connect), and vaginal ovules (Polybactum). Distributed through pharmacies and healthcare channels.
3. Dietary Supplements: Nutritional supplements for preconception, pregnancy, postpartum, and fertility (NATALBEN range: Préconception, Grossesse, Grossesse ORO, Mama; ANDROMAS for male fertility; OVUNOL for female fertility; FERTIFOL). Sold through pharmacies.
4. Cosmetics: Cosmetic products including Zelesse intimate care wash, distributed through pharmacy channels.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

EFFIK is a French pharmaceutical laboratory that develops, manufactures, and distributes prescription medicines, medical devices, and dietary supplements primarily for women's health. Its portfolio covers contraception (oral pills), fertility and preconception supplementation, pregnancy support, menopause management, infectious diseases (antifungals, bacterial vaginosis), and intimate comfort products, plus an ALS neurology franchise and rare-disease initiatives through its ITALFARMACO parent group.

Product overview

EFFIK is a French pharmaceutical laboratory founded in 1992 specializing in women's health, with operations since 2016 expanding into neurology. The company offers a diversified portfolio spanning medications, dietary supplements, and medical devices. In gynecology, the portfolio includes: contraceptive medications (TRIAFEMI, TRIAFEMI Continu, DROSPIBEL, DESOBEL, CARLIN, FEMI); fertility products (ANDROMAS and OVUNOL dietary supplements); pregnancy/postpartum supplements (NATALBEN Preconception, NATALBEN Grossesse, NATALBEN Grossesse ORO, NATALBEN Mama, plus CARIBAN medication and FERTIFOL); menopause treatments (ESTIMA capsules and BLISSEL vaginal gel); infectious disease products (LOMEXIN cream/capsules, TERLOMEXIN, BEAGYNE, GELIOFIL Protect, POLYBACTUM medical devices); and intimate comfort products (AINARA vaginal gel, ZELESSE intimate wash). In therapeutic products, EFFIK offers GYNEFFIK 2.0 and GYNEFFIK Connect pelvic floor electrostimulators for urinary incontinence, NATECAL calcium/vitamin D supplements, and TEGLUTIK for ALS treatment. The company operates as a unified product portfolio rather than a platform architecture, serving gynecologists, pharmacists, midwives, and patients through pharmaceutical, supplement, and medical device channels.

Differentiator

Problem solved

Functional benefit

Brands

• NATALBEN: Range of nutritional supplements for preconception, pregnancy, and postpartum (NATALBEN Préconception, Grossesse, Mama, Grossesse ORO).
• GynEffik
• Gyna
• AINARA
• Zelesse

Products and services

• TRIAFEMI contraceptive range Triphasic oral contraceptive pill containing Norgestimate/Ethinylestradiol, also available in a continuous-use version, prescribed by gynecologists and dispensed through pharmacies.
• DROSPIBEL contraceptive range Monophasic oral contraceptive pills containing Ethinylestradiol/Drospirenone available in two estrogen doses, prescribed for contraception through pharmacies.
• DESOBEL contraceptive range Monophasic oral contraceptive pills containing Desogestrel/Ethinylestradiol available in two progestin doses for women's contraception.
• CARLIN contraceptive range Monophasic oral contraceptive pills containing Gestodene/Ethinylestradiol available in two progestin doses for women's contraception.
• FÉMI contraceptive pill Monophasic oral contraceptive pill containing Norgestimate/Ethinylestradiol, prescribed for women seeking hormonal contraception.
• ANDROMAS dietary supplement Powder dietary supplement for male fertility containing myo-inositol, Quatrefolic 5-MTHF, vitamin D, selenium, zinc, and coenzyme Q10.
• OVUNOL dietary supplement Powder dietary supplement for female fertility containing myo-inositol, Quatrefolic 5-MTHF, iodine, selenium, vitamin D, and zinc.
• NATALBEN Preconception Dietary supplement for preconception containing Quatrefolic 5-MTHF, vitamin B12, zinc, and iodine to support reproductive health.
• NATALBEN Grossesse Dietary supplement for pregnancy containing omega-3, vitamins, minerals, and lutein to support fetal development and maternal well-being.
• NATALBEN Grossesse ORO Vegan-certified orodispersible pregnancy supplement in powder form that dissolves in the mouth without water.
• NATALBEN Mama Postpartum and breastfeeding dietary supplement containing omega-3, vitamins, minerals, lutein, and taurine for maternal recovery and infant development.
• CARIBAN 10 mg/10 mg Modified-release prescription capsule containing doxylamine succinate/pyridoxine hydrochloride for treating nausea and vomiting during pregnancy.
• FERTIFOL 400 µg Folic acid supplement tablet for preconception and pregnancy used to prevent neural tube defects.
• ESTIMA progesterone capsules Progesterone soft capsules available in 100 mg and 200 mg doses for oral or vaginal administration in menopausal hormone therapy.
• BLISSEL 50 µg/g vaginal gel Vaginal gel containing estriol for treating vulvovaginal atrophy symptoms in menopausal women.
• LOMEXIN antifungal range Fenticonazole nitrate in soft vaginal capsule (600 mg) and vaginal cream (2%) formulations for treating fungal vaginal infections.
• TERLOMEXIN 200 mg Vaginal soft capsule containing fenticonazole nitrate (200 mg) for treatment of vaginal candidiasis.
• GELIOFIL Protect vaginal gel Class IIa CE-marked vaginal gel medical device with triple action (protective barrier, symptom relief, flora restoration) for treating bacterial vaginosis using lactic acid and lactobacillus-friendly pH.
• POLYBACTUM vaginal ovule Class IIa CE-marked vaginal ovule medical device with polycarbophile and lauryl glucoside providing a bacteriostatic barrier against Gardnerella Vaginalis to prevent bacterial vaginosis recurrence.
• BEAGYNE 150 mg Prescription capsule containing fluconazole (150 mg) for treatment of vaginal fungal infections.
• AINARA vaginal gel Class IIa CE-marked non-hormonal vaginal gel with dual moisturizing and lubricating action for vulvovaginal atrophy and dryness relief.
• ZELESSE intimate wash Cosmetic intimate wash lotion enriched with Burdock extract, Aloe vera, and Chamomile for daily intimate hygiene and relief of vulvovaginitis symptoms.
• TEGLUTIK 5 mg/ml Oral suspension containing riluzole (5 mg/ml) for treatment of Amyotrophic Lateral Sclerosis (ALS), launched in 2016 as part of EFFIK's neurology franchise.
• GYNEFFIK pelvic floor electrostimulators Class IIa CE-marked pelvic floor electrostimulator devices (wired GYNEFFIK 2.0 and smartphone-connected GYNEFFIK Connect) for home rehabilitation of female urinary incontinence, including stress, urge, and mixed forms.
• NATECAL VITAMINE D3 600 mg/400 IU Orodispersible tablet containing calcium and cholecalciferol (vitamin D3) for mineral supplementation.
• ETHINYLOESTRADIOL EFFIK 50 µg Oral tablet containing ethinylestradiol (50 µg) for hormonal therapy.

Quantifiable outcome

• 94/100 on the Gender Equality Index (Index Égalité Femmes/Hommes) for 2025
• +1 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered flagship, core and minor.

• ARSLA (Association pour la Recherche sur la Sclérose Latérale Amyotrophique)flagshipStrategic or Co-development Partner · 1 January 2022Since 2022, EFFIK supports ARSLA through training projects for healthcare teams and solidarity events including the Course des Héros and Défie la SLA races. EFFIK is committed to improving the care pathway for ALS patients and their caregivers through ongoing partnerships with patient associations and healthcare professionals.
• ITALFARMACO GroupcoreStrategic or Co-development Partner · 1 January 2015ITALFARMACO is the parent group of EFFIK. EFFIK joined the ITALFARMACO group in 2015. ITALFARMACO develops, manufactures, and commercializes pharmaceutical products across more than 60 countries with over 3,100 employees globally and annual revenue of €759M. The group invests more than 10% of revenue in R&D and has a portfolio of 50+ specialties spanning Women's Health, Analgesia, Cardiovascular, CNS, Dermatology, Digestive, Locomotor, Oncology, Respiratory, and Oral Hygiene. EFFIK operates as the French subsidiary of the Italian group.
• Eco-organismes (Ecosystem, Adelphe, Cyclamed)minorOthersEFFIK is a member of eco-organisms for pharmaceutical packaging recycling: Ecosystem (household packaging), Adelphe (additional packaging), and Cyclamed (unused medicines). This supports EFFIK's environmental commitment to responsible product end-of-life management.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Regional players

• Pierre Fabre: French-headquartered pharmaceutical and dermo-cosmetics company with a diversified portfolio including women's health and intimate care OTC. Comparable on French-market presence and category overlap but broader and more diversified than EFFIK's specialist focus.

Emerging players

• IBSA Pharma: IBSA is a Swiss specialty pharma with women's-health offerings in fertility and gynecology. Comparable on therapeutic areas but smaller and with different geographic emphasis — relevant emerging peer in the women's-health specialty space.

Broad incumbents

• Sandoz: Sandoz, the Novartis generics and biosimilars spin-off, distributes women's-health products including oral contraceptives and HRT across Europe. Comparable on product categories and channel presence, but positioned as a broad incumbent rather than a focused women's-health specialist.
• Bayer Pharmaceuticals: Bayer operates a substantial women's-health franchise spanning oral contraceptives (Yaz, Yasmin), IUDs (Mirena), and HRT. Comparable on product categories but vastly larger, broader, and global — a broad incumbent rather than direct specialist peer.
• Organon: Organon was spun off from Merck in 2021 as a global women's-health pure-play across contraception, fertility, HRT, and biosimilars. Operates in many of the same therapeutic categories as EFFIK but with significantly greater geographic reach and resources.

Direct peers

• Laboratoires IPRAD: French specialty pharmaceutical laboratory with overlapping women's-health portfolio including contraception, menopause, and intimate health. Direct French-market competitor with similar scale, channel, and HCP-targeting approach.
• Theramex: Theramex is a specialty women's-health pharmaceutical company (contraception, HRT, fertility) headquartered in Monaco with strong French market presence. Closest direct comparable to EFFIK in therapeutic focus, channel model, and French/European footprint.
• Besins Healthcare: Besins Healthcare is a privately-held specialty pharma focused on hormone replacement therapy, reproductive medicine, and women's health. Directly comparable to EFFIK on HRT/menopause franchise and European market focus.
• Gedeon Richter: Hungarian-headquartered specialty pharma with a sizable women's-health franchise including oral contraceptives, HRT, and fertility products. Comparable to EFFIK on contraceptive and women's-health product mix, though larger and more geographically diversified.
• Exeltis: Exeltis is the women's-health specialty division of Chemo Group, focused on contraception, fertility, pregnancy, and menopause across 40+ countries. Closely comparable mid-sized specialty player targeting the same prescribers and patient populations as EFFIK.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EFFIK